drugset
drugset / Trial / NCT02809976

Topical Ruxolitinib for the Treatment of Vitiligo

NCT02809976 ↗

Phase 2 Completed 11 enrolled Tufts Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Timeline

Start
2016-01
Primary completion
2017-01
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications

vitiligo